Brief: Arcus Outlines Plans For Casdatifan And Its Inflammation Programs
07/01/2026 21:36
Jan 7 (Reuters) - Arcus Biosciences Inc RCUS.N: ARCUS BIOSCIENCES INC - PLANS THREE DATA READOUTS FOR CASDATIFAN IN 2026 ARCUS BIOSCIENCES INC - EXPECTS TO FUND OPERATIONS UNTIL SECOND HALF OF 2028 Source text: ID:nBw6m2tTza Further company coverage: RCUS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering